Palvella Therapeutics Balance Sheet
NASDAQ: PVLAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Palvella Therapeutics financial position
At the end of fiscal 2025, Palvella Therapeutics reported total assets of $59.6 million, down 32.5% from a year earlier against total liabilities of $31.6 million. Shareholders' equity stood at $28.0 million, or 47.0% of assets. The company held $58.0 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 5.20, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Palvella Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 57.98M | 83.60M | 7.35M | 38.63M | 117.76M | 70.44M | 62.26M | 74.87M | 37.88M | 29.36M |
| Short-Term Investments | 0 | — | 8.97M | 20.53M | 0 | 0 | 41.89M | 53.24M | 34.75M | 0 |
| Receivables | 0 | 358.00K | 0 | 5.81M | 3.31M | 1.71M | 6.79M | 2.70M | 15.55M | 57.00K |
| Total Current Assets | 58.99M | 88.23M | 7.55M | 73.42M | 127.63M | 75.72M | 115.01M | 135.38M | 89.79M | 32.67M |
| Property, Plant & Equipment | — | — | 0 | 16.99M | 19.12M | 22.05M | 19.50M | 5.05M | 4.03M | 2.26M |
| Long-Term Investments | — | — | — | — | — | — | — | 0 | 9.92M | 0 |
| Total Assets | 59.56M | 88.23M | 7.55M | 95.49M | 153.56M | 105.01M | 141.10M | 141.34M | 103.88M | 35.06M |
| Accounts Payable | 4.59M | 4.59M | 936.00K | 4.15M | 8.61M | 1.79M | 5.80M | 3.35M | 2.45M | 2.39M |
| Total Current Liabilities | 11.34M | 12.04M | 2.36M | 36.58M | 50.56M | 22.14M | 27.00M | 48.08M | 45.77M | 8.38M |
| Total Liabilities | 31.58M | 25.63M | 11.43M | 67.56M | 102.81M | 73.98M | 89.75M | 101.41M | 92.35M | 9.84M |
| Shareholders' Equity | 27.98M | 62.61M | -74.48M | -93.78M | 50.76M | 31.03M | 51.35M | 39.94M | 11.52M | 25.23M |
| Retained Earnings | -135.45M | -93.73M | -76.30M | -290.42M | -257.14M | -211.41M | -174.18M | -147.07M | -120.31M | -102.67M |
| Net Cash (Debt) | 57.98M | 83.60M | 16.32M | 59.17M | 117.76M | 70.44M | 104.15M | 128.11M | 72.63M | 29.36M |
| Shares Outstanding | 12.38M | 11.01M | 1.77M | 74.52M | 72.22M | 56.00M | 55.21M | 54.15M | 45.02M | 43.06M |
This table shows 10 annual periods of Palvella Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow PVLA's reporting calendar. What is a balance sheet?